CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy.
Xiao M, Xie L, Cao G, Lei S, Wang P, Wei Z, Luo Y, Fang J, Yang X, Huang Q, Xu L, Guo J, Wen S, Wang Z, Wu Q, Tang J, Wang L, Chen X, Chen C, Zhang Y, Yao W, Ye J, He R, Huang J, Ye L.
Xiao M, et al. Among authors: guo j.
J Immunother Cancer. 2022 May;10(5):e004022. doi: 10.1136/jitc-2021-004022.
J Immunother Cancer. 2022.
PMID: 35580929
Free PMC article.